Business
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92 BERKELEY, Calif. and MAINZ, Germany,
About this update from Quantum Cyber N.v.
[{"type":"text","content":"Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92\nBERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week. This prominent event, organized by the United European Gastroenterology and scheduled to take place in Copenhagen, Denmark, from October 14th to 17th, serves as a premier platform for discussing the latest advancements and breakthroughs in the field of gastroenterology. Recognized as a key gathering in the field, UEG Week addresses critical issues in gastroenterology, providing an ideal opportunity for Mainz Biomed to engage with international gastroenterologists, oncologists, and stakeholders interested in advancing the early detection of colorectal cancer (CRC). Mainz Biomed team members will be available throughout the event showcasing ColoAlert® the Company’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer (CRC). Attendees are invited to visit the Company’s booth – located in Hall C, Stand C3-92 - to learn more about the critical significance of early colorectal cancer detection and to explore potential collaborations and partnership opportunities. Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information. Please follow us to stay up to date:LinkedInX (Previously Twitter)Facebook About ColoAlert®ColoAlert®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert® detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Dollinger et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert® will be evaluated in the FDA-registration trial ‘ReconAAsens...